News & Community

Cancer Institute NSW supported mass spectrometry infrastructure

Cancer drug monitoring and metabolite analysis by high resolution mass spectrometry (NEW)

Sydney Vital was awarded a CINSW Research Equipment grant to A/Prof Molloy at Macquarie University. Access to this instrument for NSW cancer researchers is possible through negotiated collaboration. Please contact: [email protected]

Equipment: QExactive Plus Orbitrap mass spectrometer and UPLC

Use: High-resolution, accurate mass (HRAM), mass spectrometry (MS) platform dedicated to the measurement of small molecule cancer chemotherapy drugs, endogenous metabolites and other non-protein biomolecules in samples from patients and cancer model systems. This new infrastructure will support: i) medical oncologists towards individualising patient drug dosing to optimise management and improve outcomes, and ii) research scientists to investigate biomolecular aspects of cancer development and progression.

 Mass Spectrometers for targeted proteomics

CINSW with co-funding from  APAF and Macquarie University have awarded A/Prof Mark Molloy mass spectrometers to support translational cancer research in NSW. Successful grants have enabled the purchase of cutting-edge instruments for discovery oriented proteomics (2 x TripleTOF 5600 equipped with nanoLC) and targeted proteomics (5500 QTRAP equipped with nanoUPLC). Co-investigators of these awards include: •    Prof Stephen Clarke (RNSH)
•    A/Prof Beric Henderson (WMI)
•    Dr Maija Kohonen-Corish (Garvan Institute)
•    Dr Kellie Charles (University of Sydney)
•    Prof. Nico van Zandwijk (ADRI)
•    Prof. Rob Baxter (Kolling Institute)
•    Dr. Lisa Horvath (Sydney Cancer Centre)
•    Prof. Maria Kavallaris (CCIA)
•    Prof. Nicki Packer (Macquarie University)
•    A/Prof. Graham Robertson (ANZAC Institute)

We welcome new collaborations in translational cancer research for NSW-based researchers with projects aligned with the objectives of the Northern Translational Cancer Research Unit (

Macquarie University partners in $19.3 million boost for translational cancer research

Read more:

Please contact A/Prof Mark Molloy to discuss at [email protected]